Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of ASP2998 as Monotherapy and in Combination With Standard Therapies in Participants With Locally Advanced Unresectable or Metastatic Solid Tumors

Next Previous
Trial Profile

A Phase 1b/2 Study of ASP2998 as Monotherapy and in Combination With Standard Therapies in Participants With Locally Advanced Unresectable or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASP 2998 (Primary) ; Carboplatin; Enfortumab vedotin; Pembrolizumab
  • Indications Adenocarcinoma; Bladder cancer; Carcinoma; Gastric cancer; HER2 negative breast cancer; Non-small cell lung cancer; Oesophageal cancer; Pelvic cancer; Renal cancer; Solid tumours; Transitional cell carcinoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Astellas Pharma Global Development

Most Recent Events

  • 29 Jan 2026 Status changed from not yet recruiting to recruiting.
  • 23 Dec 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top